Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Meehan, Maria ^a,b   Parthasarathi, Laavanya ^a,b   Moran, Niamh ^a   Jefferies, Caroline A ^a   Foley, Niamh ^a,b   Lazzari, Elisa ^a   Murphy, Derek ^a   Ryan, Jacqueline ^a,b   Ortiz, Berenice ^c   M Fabius, Armida W ^c   Chan, Timothy A ^c   Stallings, Raymond L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AURKA; MYCN; Neuroblastoma; PTPRD; Tumor suppressor

Indexed keywords

AURORA A KINASE; MYCN PROTEIN; PROTEIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE RECEPTOR DELTA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; AURORA KINASE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; TYROSINE;

ARTICLE; CANCER RISK; GENE AMPLIFICATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STABILITY; UPREGULATION; APOPTOSIS; ENZYME STABILITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MORTALITY; PHOSPHORYLATION; PROTEIN BINDING; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; ENZYME STABILITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; NEUROBLASTOMA; ONCOGENE PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2; TUMOR SUPPRESSOR PROTEINS; TYROSINE;

EID: 84856436143     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-6     Document Type: Article

References (32)

1. Wang J, Bixby JL. Receptor tyrosine phosphatase-delta is a homophilic, neurite-promoting cell adhesion molecular for CNS neurons. Mol Cell Neurosci 1999, 14:370-384. 10.1006/mcne.1999.0789, 10588391.
2. Giefing M, Zemke N, Brauze D, Kostrzewska-Poczekaj M, Luczak M, Szaumkessel M, Pelinska K, Kiwerska K, Tonnies H, Grenman R, et al. High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. Genes Chromosomes Cancer 2011, 50:154-166. 10.1002/gcc.20840, 21213369.
3. Purdie KJ, Lambert SR, Teh MT, Chaplin T, Molloy G, Raghavan M, Kelsell DP, Leigh IM, Harwood CA, Proby CM, Young BD. Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer 2007, 46:661-669. 10.1002/gcc.20447, 2426828, 17420988.
4. Sato M, Takahashi K, Nagayama K, Arai Y, Ito N, Okada M, Minna JD, Yokota J, Kohno T. Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. Genes Chromosomes Cancer 2005, 44:405-414. 10.1002/gcc.20253, 16114034.
5. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O'Meara A, Breatnach F. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 2006, 66:3673-3680. 10.1158/0008-5472.CAN-05-4154, 16585193.
6. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA 2009, 106:9435-9440. 2687998, 19478061.
7. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005, 65:5561-5570. 10.1158/0008-5472.CAN-04-4603, 15994928.
8. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007, 67:2632-2642. 10.1158/0008-5472.CAN-06-4152, 17363583.
9. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 2010, 49:342-352. 2921682, 20073072.
10. Nair P, De Preter K, Vandesompele J, Speleman F, Stallings RL. Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas. Genes Chromosomes Cancer 2008, 47:197-202. 10.1002/gcc.20521, 18050303.
11. Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, et al. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 2008, 68:10300-10306. 10.1158/0008-5472.CAN-08-3272, 2760967, 19074898.
12. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M, Green R, Lee E, Smoot DT, Ashktorab H. Distinct high-profile methylated genes in colorectal cancer. PLoS One 2009, 4:e7012. 10.1371/journal.pone.0007012, 2737306, 19750230.
13. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203-216. 10.1038/nrc1014, 12612655.
14. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116. 10.1056/NEJM198510313131802, 4047115.
15. Shang X, Burlingame SM, Okcu MF, Ge N, Russell HV, Egler RA, David RD, Vasudevan SA, Yang J, Nuchtern JG. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 2009, 8:2461-2469. 10.1158/1535-7163.MCT-08-0857, 19671766.
16. Pulido R, Serra-Pages C, Tang M, Streuli M. The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1. Proc Natl Acad Sci USA 1995, 92:11686-11690. 10.1073/pnas.92.25.11686, 40467, 8524829.
17. Woodings JA, Sharp SJ, Machesky LM. MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta. Biochem J 2003, 371:463-471. 10.1042/BJ20021962, 1223315, 12570871.
18. Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV. Aurora A, meiosis and mitosis. Biol Cell 2004, 96:215-229. 10.1016/j.biolcel.2003.09.008, 15182704.
19. Pulido R, Krueger NX, Serra-Pages C, Saito H, Streuli M. Molecular characterization of the human transmembrane protein-tyrosine phosphatase delta. Evidence for tissue-specific expression of alternative human transmembrane protein-tyrosine phosphatase delta isoforms. J Biol Chem 1995, 270:6722-6728. 10.1074/jbc.270.12.6722, 7896816.
20. Ferrari S, Marin O, Pagano MA, Meggio F, Hess D, El-Shemerly M, Krystyniak A, Pinna LA. Aurora-A site specificity: a study with synthetic peptide substrates. Biochem J 2005, 390:293-302. 10.1042/BJ20050343, 1188270, 16083426.
21. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78. 10.1016/j.ccr.2008.12.005, 19111882.
22. Ohashi S, Sakashita G, Ban R, Nagasawa M, Matsuzaki H, Murata Y, Taniguchi H, Shima H, Furukawa K, Urano T. Phospho-regulation of human protein kinase Aurora-A: analysis using anti-phospho-Thr288 monoclonal antibodies. Oncogene 2006, 25:7691-7702. 10.1038/sj.onc.1209754, 16785988.
23. Kitajima S, Kudo Y, Ogawa I, Tatsuka M, Kawai H, Pagano M, Takata T. Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer. PLoS One 2007, 2:e944. 10.1371/journal.pone.0000944, 1976594, 17895985.
24. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, Prenter S, Bray I, Watters KM, Higgins D, Stallings RL. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One 2009, 4:e8154. 10.1371/journal.pone.0008154, 2781550, 19997598.
25. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog 2011, 50:403-411. 10.1002/mc.20722, 21557326.
26. van der Vaart B, Manatschal C, Grigoriev I, Olieric V, Gouveia SM, Bjelic S, Demmers J, Vorobjev I, Hoogenraad CC, Steinmetz MO, Akhmanova A. SLAIN2 links microtubule plus end-tracking proteins and controls microtubule growth in interphase. J Cell Biol 2011, 193:1083-1099. 10.1083/jcb.201012179, 3115796, 21646404.
27. Ferrari S. Protein kinases controlling the onset of mitosis. Cell Mol Life Sci 2006, 63:781-795. 10.1007/s00018-005-5515-3, 16465440.
28. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010, 10:825-841. 10.1038/nrc2964, 21102634.
29. Macurek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB, Medema RH. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008, 455:119-123. 10.1038/nature07185, 18615013.
30. Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B, Eggert A, Berthold F, Fischer M. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin Cancer Res 2011, 17:731-741. 10.1158/1078-0432.CCR-10-1129, 21169242.
31. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010, 55:26-34. 2874079, 20108338.
32. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, et al. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 2011, 68:1291-1304. 10.1007/s00280-011-1618-8, 3215888, 21448591.